WT1


Also found in: Acronyms.

WT1

A gene on chromosome 11p13 that encodes a transcription factor with a central role in urogenital development. WT1 displays complex tissue-specific and polymorphic imprinting pattern, with biallelic and monoallelic expression from the maternal and paternal alleles in different tissues. WT1 mRNA undergoes RNA editing, a tissue-restricted and developmentally regulated process.

Molecular pathology
WT1 is mutated in a small subset of patients with Wilm's tumours.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
WT1 expression results suggested a strong role in tumorigenesis, which is consistent with other studies.
Catapult Therapy TCR Ltd is a special purpose company set up by CGT Catapult, UCL Business and Imperial Innovations, and managed by CGT Catapult, for the development of the WT1 T cell receptor cell therapy discovered through research at University College London and Imperial College London.
Recent studies have demonstrated that mutations in WT1 can lead to syndromic forms of steroid-resistant NS (SRNS), such as Denys-Drash or Frasier syndrome, and can cause isolated SRNS [8, 9].
Antibodies were from Santa Cruz Biotechnology: p53 (sc-81168); Cell signaling: E-Cadherin (cs-3195), HDAC6 (cs-7558), phospho-Ser15-p53 (cs-9284), yH2AX (cs-9718); Abcam: WT1 (ab89901; ab201948); Enzo: HSP90 (ADI-SPA-830-F); Millipore: ac-H3 (06-599); Sigma: ac-Tubulin (T7451); BD Biosciences: [beta]-Catenin (610153), RAC1 (610650); Pharmingen: Poly (ADPRibose) Polymerase (PARP1) (556362).
The most frequently mutated genes in NK-AML occur in the following genes: nucleophosmin (NPM1), Fms-related tyrosine kinase 3 (FLT3) and DNA methyltransferase 3A (DNMT3A), Ten-eleven translocation-2 (TET2), isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2), CCAAT/enhancer binding protein alpha (CEBPA), NRAS, Additional sex comb-like 1 (ASXL1), WT1 and runt-related transcription factor-1 (RUNX1).
Recent reports on WT1 expression analysis on human breast cancer by immunohistochemistry and RTPCR show controversial results, Silberstein et al.
Immunoreactivity of WT1 was evaluated according to the staining intensity and localization of the tumor cell nuclei and graded 0, 1+, 2+, and 3+, corresponding to absent, focal/weak, moderate, and intense expression.
The WT2 has the same features as the WT1, but offers improved interfacing capabilities.
Later on, these results were confirmed in a pilot study using human samples.[63] Wilms tumor-1 protein (WT1), a protein secreted by renal epithelial cells and detected in uEVs, is thought to be related to podocyte injury.
Taking the specimen WT1 as an example, the correlation coefficient is 0.979 and the fitting effect is superior.
The most commonly found marker was Cytokaratin which was present in 71.4% of the mesothelioma patients, followed by Calretinin (57.1%), and WT1 (50%).